The Safelock AML project

Purpose and goal: ** Denna text är maskinöversatt **

The ability to detect rare variants of DNA sequences can provide more accurate diagnostics and enable monitoring of disease processes and therapy response. For example In patients diagnosed with Akut Myeloid Leukemi (AML) or Myelodysplastiskt Syndrom (MDS), the outcome is highly dependent on treatment optimization and early detection of residual or relapsing mutations. The project aims to revolutionize treatment optimization and relapse detection in AML and MDS patients.

Expected results and effects:

The project aims to revolutionize treatment optimization and relapse detection of Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS). The technology is based around an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. By implementing this new detection technology in labs, clinicians will be able to better access treatment response and detect relapses earlier by using easily accessible blood samples rather than the conventional bone marrow samples that are both burdensome and costly.

Approach and implementation: ** Denna text är maskinöversatt ** The project is divided into five parts, 1. Assay development. Develop relevant panels for AML and MDS 2. Assay validation. Quality control and approval of assay targets 3. Transfer Validation/ LDT development. Disqualification of tests in lab environment

4. Re-testing of clinical samples. Retrospective analysis of patient cohort 5. Clinical benefit analysis. Analysis of retrospective data for assessment of changed routines. 6. Publication